EPHA4 and Alzheimer disease: Oral administration of Rhy reduced EphA4 activity in APP/PS1 transgenic mice as well as restored impaired recurrent potentiation in the hippocampus, substantiating the beneficial effects of Rhy on synaptic dysfunction in AD [69].